This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adelstein, D. J. Articles by LeBlanc, M. Search for Related Content PubMed PubMed Citation Articles by Adelstein, D. J. Articles by LeBlanc, M.

Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?

David J. Adelstein, Michael LeBlanc

From the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH; and the Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

Address reprint requests to David J. Adelstein, MD, Department of Hematology and Medical Oncology, Desk R-35, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; e-mail: adelstd{at}ccf.org

The use of systemic chemotherapy before definitive locoregional management, or induction chemotherapy, has been a theoretically attractive and well-studied approach in the management of squamous cell head and neck cancer. Although a decrease in distant metastases has frequently been observed, an improvement in survival from induction has been difficult to demonstrate. When chemotherapy and radiation are used concomitantly, however, an improvement in both survival and locoregional control can be identified, and this has led to the adoption of concurrent chemoradiotherapy as a standard of care for these patients. With this improvement in locoregional control, distant metastases have become a more frequently recognized cause of treatment failure, suggesting that an intervention, such as induction chemotherapy, directed at improving distant control might now be of some importance in improving overall treatment success. The recent development of taxane-containing, three-drug induction regimens that are capable of producing significantly better response rates than the older cisplatin and fluorouracil combination has also raised the possibility of a new and more important role for induction. The results of phase II investigations using this kind of a sequential schedule of induction chemotherapy followed by concurrent chemoradiotherapy have been encouraging, and phase III trials are now underway. This treatment approach remains investigational however, and these phase III studies are critical. The current randomized trials are reviewed and discussed.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				D. J. Adelstein Redefining the Role of Induction Chemotherapy in Head and Neck Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3117 - 3119. [Full Text] [PDF]

				M. S. Kies, G. R. Blumenschein Jr., and D. I. Rosenthal Sequential Chemoradiation for Squamous Cell Carcinoma of the Head and Neck ASCO Educational Book, January 1, 2008; 2008(1): 235 - 238. [Abstract] [Full Text] [PDF]

				J. B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, M. Degardin, J. S. Stewart, S. Jelic, J. Betka, J. H. Preiss, et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer N. Engl. J. Med., October 25, 2007; 357(17): 1695 - 1704. [Abstract] [Full Text] [PDF]

				J. K. Salama, T. Y. Seiwert, and E. E. Vokes Chemoradiotherapy for Locally Advanced Head and Neck Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126. [Full Text] [PDF]

				A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis Head and Neck Cancer: Recent Advances and New Standards of Care J. Clin. Oncol., June 10, 2006; 24(17): 2603 - 2605. [Full Text] [PDF]